CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy.

Name: CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy.
Author: Ramachandran, Raja

CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy. — المؤلف: Ramachandran, Raja — Kidney international reports Jan 2017

المؤلف: Ramachandran, Raja
النشر: Kidney international reports Jan 2017
الوصف: 89-90 p.